Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.91 percent. This is a 62.65 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $13.77 million which beat the analyst consensus estimate of $11.56 million by 19.07 percent. This is a 7.23 percent increase over sales of $12.84 million the same period last year.
Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) Estimate, Sales $13.77M Beat $11.56M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.